Evidence map›Paper›PMID 33637387›Full record

ReviewVaccine2021

Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

Flor M Munoz, Jakob P Cramer, Cornelia L Dekker, Matthew Z Dudley, Barney S Graham, Marc Gurwith, Barbara Law, Stanley Perlman, Fernando P Polack, Jonathan M Spergel and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Analysis of BeyfortusCurrent issues in molecular biology · 2024
    Review
  18. Review
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Flor M MunozDepartments of Pediatrics, Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA. Electronic address: florm@bcm.edu.
Jakob P CramerCoalition for Epidemic Preparedness Innovations, CEPI, London, UK.
Cornelia L DekkerDepartment of Pediatrics, Stanford University School of Medicine, CA, USA.
Matthew Z DudleyInstitute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.
Marc GurwithSafety Platform for Emergency Vaccines, Los Altos Hills, CA, USA.
Barbara LawSafety Platform for Emergency Vaccines, Manta, Ecuador.
Stanley PerlmanDepartment of Microbiology and Immunology, Department of Pediatrics, University of Iowa, USA.
Fernando P PolackFundacion Infant, Argentina.
Jonathan M SpergelDivision of Allergy and Immunology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania, PA, USA.
Eva Van BraeckelDepartment of Respiratory Medicine, Ghent University Hospital, and Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium.
Brian J WardResearch Institute of the McGill University Health Center, Montreal, Quebec, Canada.
Arnaud M DidierlaurentCenter of Vaccinology, University of Geneva, Switzerland.
Paul Henri LambertCenter of Vaccinology, University of Geneva, Switzerland.
Brighton Collaboration Vaccine-associated Enhanced Disease Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is a Brighton Collaboration Case Definition of the term "Vaccine Associated Enhanced Disease" to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission.

Indexed as

COVID-19VaccinesCOVID-19 VaccinesData CollectionHumansImmunizationSARS-CoV-2COVID-19 VaccinesVaccinesAdverse eventCase definitionEnhanced diseaseGuidelinesImmunizationRespiratorySystemic diseaseVaccine

Identifiers

PMID33637387
PMCPMC7901381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.